Finance

Amazon Poised to Join Tech Titans in the $3 Trillion Market Cap Summit by 2026

AWS Growth and E-Commerce Efficiency Drive Amazon's Path to a New Valuation Milestone

Amazon, currently valued at $2.48 trillion, is positioned to break into the exclusive $3 trillion market capitalization tier by the end of 2026. This ...

Bitcoin Price Outlook for 2026: Diverse Predictions Spotlight Market Uncertainty

Institutional interest and regulatory clarity drive bullish sentiment while cautious scenarios foresee consolidation or decline

Forecasts for Bitcoin's price in 2026 reveal a predominantly optimistic outlook, though projections vary widely. Major financial institutions and indu...

Duff & Phelps Trims Rexford Industrial Stake: A Signal of Moderating Growth in Industrial REITs

Significant reduction in Rexford Industrial Realty shares by a major fund reflects evolving investor focus amid steady operational metrics

Duff & Phelps Investment Management reduced its position in Rexford Industrial Realty during the third quarter, selling approximately 1.79 million sha...

Newmont Corporation Shares Decline Amid Gold Price Retraction From Recent Highs

Gold's Pullback from Record Peaks Weighs on Precious Metals Stocks Including Newmont

Newmont Corporation's stock experienced a notable decline on Monday afternoon, coinciding with a retreat in gold prices from recently achieved record ...

Why Uber Remains a Core Holding for the Long Term

A Close Look at Uber's Market Position and Financial Strength Signals Durability

While the stock market seldom offers truly permanent investments, Uber stands out as a company worth long-term ownership. As a dominant global ridesha...

WORK Medical Technology Group Gains Momentum After Regulatory Approval of AI-Driven Blood Analyzer

Regulatory milestones and distribution agreements bolster expectations for WORK Medical’s innovative hematology device

Shares of WORK Medical Technology Group (NASDAQ:WOK) have experienced significant gains following regulatory approval to manufacture a novel AI-powere...

Arrowpoint Investment Partners Fully Divests XPeng Stake Worth Nearly $9 Million

Strategic Portfolio Rebalancing Sees Complete Exit from Chinese Electric Vehicle Maker

In a recent regulatory filing, Arrowpoint Investment Partners (Singapore) disclosed the sale of its entire 500,000-share stake in XPeng Inc., valued a...

Alphabet: A Reliable Contender in AI Investment Over Risky Penny Stocks

Established technology giant Alphabet offers a comprehensive AI portfolio and financial strength, positioning it as a prudent long-term investment in artificial intelligence.

The excitement surrounding artificial intelligence has driven many investors toward high-risk penny stocks with uncertain futures. In contrast, Alphab...

Navigating Economic Uncertainty: A Look at Recent Data and Market Implications

Assessing Consumer Strength, Inflation, and Investment Strategies Amid Data Gaps and Conflicting Signals

Recent economic data releases following a significant reporting hiatus caused by a government shutdown present a mixed and uncertain picture of the U....

Society Pass Unveils New Live Commerce Platform in Thailand, Driving Stock Surge

Singapore-based e-commerce firm aims for $10 million revenue in 2026 with TMG Social launch

Shares of Society Pass Incorporated (NASDAQ:SOPA) experienced a significant increase following the company's announcement of TMG Social, a live commer...

Analyzing Micron Technology's Market Position and Valuation Amid Memory Hardware Demand

Examining Micron's valuation and growth prospects in the context of current market conditions and AI-driven memory shortages

Micron Technology operates in the memory hardware sector, a segment crucial yet often overlooked within the broader tech industry, especially amid the...

Ultragenyx Pharmaceutical Plunges Amid Phase 3 Trial Setbacks; Market Sees Varied Stock Movements

Shares of Ultragenyx tumble 42% following Phase 3 study results, while other biotech and tech stocks show mixed performance

Ultragenyx Pharmaceutical's stock declined dramatically after clinical setbacks in pivotal Phase 3 trials for setrusumab, a treatment targeting Osteog...